Weighted Average Of US Dollar Rate In NASDAQ OMX Armenia As Of February 7 Was 363,75 Drams For $1

YEREVAN, February 7. /ARKA/. Weighted average of US dollar rate by transactions in NASDAQ OMX Armenia as of February 7, 2011 reduced by 0.25 points compared with the indicator of previous auctions as of February 4 making 363.75 drams for $1.

According to news agency “ARKA”, today by US dollars 11 transactions in total amount of $1.3 million (in dram equivalent – 472.9 million drams) were implemented.

There are no transactions by EURO as of February 7 in NASDAQ OMX Armenia stock exchange.

Mid-market rates as of February 7 are $1 – 364.3, €1 – 495.48 drams. G.K.–0—

Date Code Average weighted change Average weighted price Price at opening Price at closing Max. price Min. price Demand Supply Number of transactions Volume (foreign currency) Volume (AMD)
07.02.11 EUR
USD -0.07% 363.75 363.75 363.75 363.75 363.75 363.51 363.7 11 1,300,000 472,875,000
spot_img

POPULAR

Record growth of Armenia’s reserves to $6.9 billion in June provided a buffer amid heightened geopolitical risks – S&P

Armenia's international reserves increased by approximately 40% year-on-year to a record $6.9 billion in June 2026, helping to strengthen the country's external reserves despite heightened geopolitical risks, according to a report by international rating agency S&P Global Ratings.

US dollar, euro, and ruble up against  Armenian dram

YEREVAN, August 20. /ARKA/. The average market exchange rate for the US dollar to the Armenian dram on the Armenian foreign exchange market as of August 20, 2026, increased by 0.3 points to 365.26 drams compared to August 19.

S&P affirms Armenia’s ratings, maintaining a positive outlook

The international rating agency S&P Global Ratings affirmed the long- and short-term sovereign ratings of the Republic of Armenia at 'BB-/B', maintaining a positive outlook, the Ministry of Finance reported.

S&P: Armenia’s banking sector is well capitalized and highly profitable

Armenia's banking sector remains well capitalized and highly profitable, supported by high net interest income and robust economic growth, according to a report from international rating agency S&P Global Ratings.

Shares of Noubar Afeyan’s Moderna soared 124% on news of a successful cancer vaccine trial

YEREVAN, August 20. /ARKA/. Shares of the biotech company Moderna soared 123.6% at the start of trading in the US on August 19, reaching a peak of $140.77, according to trading data. Shares of the pharmaceutical company Merck also rose 11.6% to $150.85, according to Forbes.ru.

LATEST NEWS

spot_imgspot_imgspot_img